70
Participants
Start Date
June 30, 2014
Primary Completion Date
March 31, 2020
Study Completion Date
March 31, 2020
Guanfacine 3mg/day
3 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
Guanfacine 1.5mg/day
1.5 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
Placebo
Yale Center for Clinical Investigations, Yale University, New Haven
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Yale University
OTHER